• Welcome, Guest. Please login or register.
    June 01, 2020, 12:22:38 AM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55292 Posts in 5909 Topics by 6204 Members
Latest Member: pareshdas1985

Forum Tip: 
Put your birthdate in your profile, under "Forum Profile Information," and it will automatically come up on our calendar.
« previous next »
Pages: 1 Go Down Print
Author Topic: Beta 0 Gene Therapy Trials to Begin Recruiting Patients  (Read 1679 times)
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8656


Will thal rule you or will you rule thal?


« on: November 17, 2017, 08:33:12 PM »

bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype

– Study to enroll approximately fifteen adult, adolescent and pediatric patients –


http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-first-patient-treated-northstar-3-hgb-212

Quote
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that the first patient has been treated in Northstar-3 (HGB-212), the company’s Phase 3 study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) with the β0/β0 genotype.

“We are excited to start our second Phase 3 study of LentiGlobin in patients with TDT,” said Dave Davidson, chief medical officer. “Early data presented at the European Hematology Association annual meeting this year indicates that our refined manufacturing process, now implemented for treatment across all of our active studies of LentiGlobin, has consistently yielded improved Drug Products with higher vector copy number and an increased proportion of transduced cells. We are optimistic that these advances will improve our ability to achieve the levels of HbAT87Q needed for the patients in this study, who have the β0/β0 genotype, to see their annual RBC transfusions dramatically reduced, if not entirely eliminated.”

“Ongoing studies of LentiGlobin in patients with TDT have indicated the potential for a durable effect, with patients seeing consistent production of HbAT87Q for more than three years after treatment,” said Alexis Thompson, MD, MPH, Ann & Robert H. Lurie Children’s Hospital of Chicago, Illinois and a primary investigator on the study. “With the introduction of the refined manufacturing process into the Northstar-2 and Northstar-3 pivotal studies, we hope our patients will produce a greater amount of hemoglobin to enhance their treatment effect, and thereby demonstrate that LentiGlobin has the potential to address the underlying genetic cause of TDT, regardless of genotype.”
Logged

Andy

All we are saying is give thals a chance.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!